Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.

Autor: Circosta P; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.; Molecular Biotechnology Center, University of Turin, Turin, Italy., Donini C; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy., Gallo S; Hematology Unit ASL Torino 4, Turin, Italy., Giraudo L; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Gammaitoni L; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Rotolo R; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy., Galvagno F; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy., Capellero S; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy., Basiricò M; Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health and Science of Turin, Turin, Italy., Casucci M; Innovative Immunotherapies Unit - Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Aglietta M; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy., Ferrero I; Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health and Science of Turin, Turin, Italy., Fagioli F; Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health and Science of Turin, Turin, Italy.; Department of Public Health and Paediatrics, University of Turin, Turin, Italy., Cignetti A; Division of Hematology and Cell Therapy, A.O. Ordine Mauriziano, Turin, Italy., Carnevale-Schianca F; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Leuci V; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Sangiolo D; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2023 Jan; Vol. 200 (1), pp. 64-69. Date of Electronic Publication: 2022 Sep 26.
DOI: 10.1111/bjh.18469
Abstrakt: Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our study provides translational bases to support clinical studies with fcCAR.CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.
(© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: